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Abstract
Liver transplantation (LT) is associated with a 2 to 
7 fold higher, age and gender adjusted, risk of de 
novo  malignancy. The overall incidence of de novo 
malignancy post LT ranges from 2.2% to 26%, and 
5 and 10 years incidence rates are estimated at 10% 
to 14.6% and 20% to 32%, respectively. The main 
risk factors for de novo  malignancy include immuno-
suppression with impaired immunosurveillance, and 
a number of patient factors which include; age, 
latent oncogenic viral infections, tobacco and alcohol 
use history, and underlying liver disease. The most 
common cancers after LT are non-melanoma skin 
cancers, accounting for approximately 37% of de novo 
malignancies, with a noted increase in the ratio of 
squamous to basal cell cancers. While these types of 
skin cancer do not impact patient survival, post-trans-
plant lymphoproliferative disorders and solid organ 
cancer, accounting for 25% and 48% of malignancies, 
are associated with increased mortality. Patients deve-
loping these types of cancer are diagnosed at more 
advanced stages, and their cancers behave more aggre-
ssively compared with the general population. Patients 
undergoing LT for primary sclerosing cholangitis (parti-
cularly with inflammatory bowel disease) and alcoholic 
liver disease have high rates of malignancies compared 
with patients undergoing LT for other indications. These 
populations are at particular risk for gastrointestinal 
and aerodigestive cancers respectively. Counseling 
smoking cessation, skin protection from sun exposure 
and routine clinical follow-up are the current approach 
in practice. There are no standardized surveillance 
protocol, but available data suggests that regimented 
surveillance strategies are needed and capable of 
yielding cancer diagnosis at earlier stages with better 
resulting survival. Evidence-based strategies are needed 
to guide optimal surveillance and safe minimization of 
immunosuppression.
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TOPIC HIGHLIGHT
Incidence, risk factors and outcomes of de novo 
malignancies post liver transplantation
2016 Liver Transplantation: Global view
Group Inc. All rights reserved.
Core tip: The risk of new cancers is significantly in-
creased after liver transplantation (LT), and is driven 
by patient factors, oncogenic viruses and lifelong 
immunosuppression. De novo  malignancy is a major 
risk factor for mortality after LT, equaling the risk of 
cardiovascular disease or infectious diseases. The risk of 
de novo  malignancies may be reduced by attention to 
patient risk factors and minimization of immunosuppre-
ssion when possible. Ultimately rigorous surveillance is 
needed to allow for early diagnosis and attenuation of 
mortality risk.
Mukthinuthalapati PK, Gotur R, Ghabril M. Incidence, risk 
factors and outcomes of de novo malignancies post liver trans-
plantation. World J Hepatol 2016; 8(12): 533-544  Available 
from: URL: http://www.wjgnet.com/1948-5182/full/v8/i12/533.
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INTRODUCTION
Liver transplantation (LT) is the definitive therapy for 
decompensated end-stage liver disease regardless of 
etiology. During the past 2 decades, the outcomes of LT 
have steadily improved as a result of more widespread 
expertise, better surgical techniques and more effective 
and better tolerated immunosuppressive agents. The 
growing number of LT recipients and improving survival
rates place particular importance on the factors that 
jeopardize long term survival. Inherent to this popu-
lation is the need for lifelong immunosuppression, 
which is associated with some broad categories of risk 
for morbidity and mortality. These include infection, 
cardiovascular risks, renal injury and cancer. When 
studied in patients surviving the early post LT period, 
de novo malignancy emerges as the leading category 
of immunosuppression associated long term mortality 
risk, accounting for approximately 21% to 25% of 
deaths[1,2]. This review summarizes current knowledge 
of de novo malignancy post LT including; epidemiology, 
pathogenesis, disease burden, clinical implications, 
preventive and surveillance considerations, while em-
phasizing risk factors and outcomes.
INCIDENCE
Multiple studies report widely varying incidence rates 
of de novo malignancy post LT, along with consider-
able variations in associated risks, cancer types and 
outcomes. The incidence of de novo malignancies in 
relatively large cohorts (subjectively defined as more 
than 150 patients) is summarized in Table 1, the last row 
of which contains the means of the respective variables. 
These include single center experiences[3-7], registry 
based studies[8-11], and the majority are retrospective 
with few exceptions[12]. Variability in de novo malignancy 
incidence rates reflect actual differences (based on 
differing cohort characteristics and risks) and artificial 
differences (based on differing methodologies and 
study design). The factors impacting actual differences 
in cancers types and their incidence may include age, 
gender, racial and geographical considerations, as well 
as the predominant underlying liver diseases and their 
associated comorbidities. Whereas artificial heterogeneity 
may be less apparent, yet could arise from variability 
in the: (1) definitions of de novo malignancy, e.g., not 
all include non-melanoma skin cancers; (2) designated 
time threshold for of exclusion of cancers that are likely 
pre-existing before LT; (3) method of identification of 
malignancies, e.g., in-center chart review vs utilization 
of cancer registries; (4) surveillance protocols and 
frequency of clinical follow up at study centers (critical 
for in-center reporting of cancer cases); (5) duration of 
follow up post LT since cancer incidence increases with 
time[8,13]; and (6) in the case of standardized incidence 
ratio (SIR) calculations, the control population used and 
type of cancers captured by the respective registries. 
In this review, we have described incidence rates of 
cancers and as well as the SIR where possible, as it 
allows age and gender adjusted risk analysis. SIR is 
calculated as the ratio of observed incidence in a cohort 
to the expected incidence in the population (hence has 
no unit). 
Cancer registry data used to calculate expected age 
and gender adjusted incidence rates for SIR estimation 
doesn’t capture non-melanoma skin cancers (NMSCs). 
Therefore SIR analyses succinctly reflect the risk of 
more life-threatening types of cancer. Interestingly, 
purely registry based analyses yield higher SIR values 
for de novo malignancy post LT, ranging from 2.2 to 
4.9[10,14-16], than 1.4 to 3.1[2,9,11,17,18] of single and multi-
center studies. The reasons for this are unclear but 
could reflect differing approaches to immunosuppression 
given the reporting bias for higher transplant volume 
centers.
RISK FACTORS FOR DE NOVO 
MALIGNANCY
The risk factors for the development of de novo mali-
gnancy after LT are not fully understood, but it is likely 
that patient, transplant and environmental factors inter-
act to shape that risk. 
Immunosuppression related risk
Over the past few decades, a better understanding of 
the role of the immune system in preventing malign-
ancy in immunocompetent individuals helped establish 
the concept of immunosurveillance[19]. Transplant reci-
pients receive lifelong immunosuppression with chronic 
impairment of immunosurveillance, which promotes 
proliferation and survival of malignant cellular clones. 
Though immunosuppressive drug dose intensity likely 
contributes to cancer risk, the evidence for this is 
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Recipient related factors
The association of specific patient factors with cancer 
risk are organized and elaborated on below.
Age: Advanced age is a well described risk factor for 
de novo malignancy[2,7,8,12,44,45], although this is not a 
universal finding[25,28]. This suggests that other factors 
may supersede age in cancer risk, though some caveats 
are notable with the extremes of age. For example 
the SIR for early PTLD was high (18.1) in pediatric LT 
recipients in one study[9], with a similar observation in 
another study[10]. In another study, LT recipients older 
than 60 had > 2 fold higher 5-year incidence of new 
cancers (> 40%) compared to younger LT recipients (< 
20%), largely due to non-skin cancers, with significantly 
higher cancer related mortality[46].
Gender and race: There is conflicting data on the 
relative risk of de novo malignancy according to gender, 
with slightly higher SIR of cancers in females in one 
registry study[14], and in males in another[45], limiting 
any meaningful conclusion. Although skin cancer risk 
would be expected to differ according to race, there 
is limited data of cancer risk in relation to race. Non-
Caucasian race was associated with a higher hazard 
ratio (HR = 2.5, 95%CI: 1.3-4.3) for non-skin cancers 
in one study, but the small size of that subgroup was 
limiting[2]. 
Indication for LT: Patients who receive LT for certain 
indications are more prone to some malignancies. 
Patients with primary sclerosing cholangitis (PSC) in 
a United States multicenter prospective observational 
study had the highest cumulative incidence of non-
skin cancer of 5.5%, 10.4%, and 21.9% at 1, 5, 
and 10 years, respectively[12]. Patients with PSC and 
inflammatory bowel disease (IBD) and an intact colon at 
the time of LT were at increased risk of gastrointestinal 
(colon) malignancy (HR = 2.34, 95%CI: 1.02-5.38)[12], 
which may not be surprising given the association of 
PSC and IBD with colon cancer risk. However, patients 
with PSC also exhibited an increased risk for PTLD, skin 
malignancies and solid organ malignancies[12]. A high 
cancer risk for LT recipients with PSC was also observed 
in an Italian study, though cancer types were not speci-
fied[47]. The reasons for generalized cancer risk are 
unclear, but may reflect immunosuppression before LT, 
and possibly vitamin D deficiency which may promote 
malignancy[48].
Alcohol use history and smoking: Many studies 
have described the carcinogenic properties of alcohol 
and smoking in immunocompetent individuals[49,50]. 
Alcoholic liver disease (ALD) is associated with increased 
cancer risk post LT[7,12,36,45,51-54]. Synergy between the 
carcinogenic effects of alcohol and smoking is well 
described[55,56]. Smokers were more likely to have 
alcoholic liver disease than non-smokers (35% vs 13%, 
anti-proliferative properties of mTOR inhibition include 
inhibition of cellular growth, proliferation, metabolism 
and angiogenesis[29]. Though there is no prospective 
randomized controlled study data currently, a number 
of retrospective studies have described lower rates of 
hepatocellular carcinoma (HCC) recurrence[30,31], and 
de novo malignancies[32,33] with mTOR inhibitors post 
LT and renal transplantation[34]. A meta-analysis of 
retrospective studies has shown that mTOR inhibitor, 
sirolimus, is of value in preventing recurrence and in-
creasing survival in those transplanted for HCC[35].
The post LT cancer risk related to anti-metabolites 
has been described for azathioprine in one study, with 
an odds ratio (OR = 3.8, 95%CI: 1.7-8.6, P = 0.004)[36]. 
Whereas mycophenolate mofetil has been shown to 
have anti-tumor properties in animal studies[37], and was 
associated with a trend towards lower risk of non-skin 
de novo malignancies post renal transplant in a large 
United States, and European/Canadian registry based 
study[38]. In a recent study of solid organ transplant, 
mycophenolate mofetil use was associated with lower 
risk of proximal colon cancer[39].
Immunosuppression induction with anti-lymphocyte 
antibodies or anti-thymocyte globulin was associated 
with increased of skin cancer in one study[9], however 
that risk was not seen in larger series using anti-
thymocyte globulin induction[2,28]. Rejection episodes 
also did not alter the risk of malignancy in LT reci-
pients[5,6,12,40]. These data suggest that higher levels of 
immunosuppression in the short term do not increase 
the long term risk of cancer. 
Immunosuppression also increases the cancer 
risk related to latent oncogenic virus infections (Table 
2)[41]. Oncogenic virus associated tumors may be more 
immunogenic than those related to other factors, and 
may regress once immunosuppression is stopped or 
minimized[42]. This provides the rationale for a decrease 
in immunosuppression as the first line intervention 
for some virus related cancers, such post-transplant 
lymphoproliferative disorder (PTLD), particularly when 
associated with Epstein-barr virus (EBV) viremia[43].
Table 2  A listing on known oncogenic viruses and the 
malignancies associated with them
Oncogenic virus Associated malignancy
EBV PTLD
Human papilloma virus Cervical, skin, oropharynx, 
anal
Human T-cell lymphotropic virus type 1 Adult T cell leukemia
Kaposi’s sarcoma-associated 
herpesvirus
KS, primary effusion 
lymphoma, castleman's 
disease 
HBV HCC
HCV HCC, PTLD1
1Role controversial. HCC: Hepatocellular carcinoma; EBV: Epstein-Barr 
virus; PTLD: Post transplant lymphoproliferative disorder; KS: Kaposi’s 
sarcoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus.
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P = 0.008) in one study[56], and patients transplanted for 
ALD were more likely to be smokers (82% vs 45%, P = 
0.001) and smoked more cigarettes per day (27 ± 15 
vs 16 ± 11, P = 0.001) in another[54]. A United Kingdom 
registry study reported a higher SIR (3.16) of de novo 
malignancy for ALD compared to all other LT indications 
(1.99)[45]. In the immunocompetent population, there is 
evidence that the increased risk of cancer due to alcohol 
abuse could be reversed by abstinence[57]. However, this 
effect may be delayed by a more than a decade[58], with 
cancer risk carried through post LT. 
History of cancer prior to LT: A history of cancer 
prior to LT was not associated with its recurrence 
after LT[8,25]. However, LT for HCC has been associated 
with an increased risk of de novo malignancy[7,44]. An 
increased incidence of non-skin cancers in patients 
with a history of non-liver cancer prior to LT (30.8% 
vs 8.3%, P = 0.001) has also been described, where it 
was additionally an independent predictor of non-skin 
de novo malignancies (HR = 2.5, 95%CI: 1.3-4.9, P 
= 0.005)[2]. This association is supported by data from 
renal transplantation studies[34,59,60]. Therefore, a prior 
history of cancer may reflect a patient’s composite 
(genetic and epigenetic) risk of malignancy. 
SITE SPECIFIC DE NOVO MALIGNANCIES
The risk of de novo malignancy is variable across a 
range of tumor types, as reported by cancer registry 
studies. These cancers are commonly grouped according 
to three broad categories including; skin cancers, PTLD 
and solid organ cancers. The risks of specific tumors 
post LT are summarized in Table 3.
Skin cancers
Skin malignancy, typically NMSC, is the most common 
malignancy after LT[2,7,9,12,40,61]. These include squamous 
cell cancer (SCC), basal cell cancer (BCC) and Kaposi’s
sarcoma (KS). Ultraviolet radiation is an important risk 
factor in the pathogenesis of skin malignancies, and 
exerts a field cancerization mutagenic effect in exposed 
areas of the skin[62-65]. In a prospective study of LT 
recipients with comprehensive dermatology follow-up,
only total pre transplant sun burden and skin charac-
teristics were found to be the risk factors for NMSC[66]. 
The relative risk of cutaneous malignancies in this 
cohort was found to be 20 fold higher than the general 
population. Conversely studies from Iran, South Korea 
and China described no to very low incidence rates of 
skin cancer, likely due to the prevalent skin types[67-69]. 
In organ transplant recipients, SCC is more common 
than BCC, in contrast to the general population[44,70]. 
Additionally, while SCC and BCC are easily surveyed and 
resected, SCC can behave more aggressively in LT reci-
pients[70,71]. In general though, LT recipients with SCC 
and BCC have similar survival to patients not developing 
de novo malignancies post LT[2,40]. 
Immunosuppression with CNIs and azathioprine 
is a significant risk factor for NMSC[72-76], but it is likely 
Table 3  A summary of ranges of reported overall incidence rates and 
standardized incidence ratios of a number of cancer types following liver transpla
ntation[2-5,7-12,14-16,28,36,47,66,110,118-120] 
Incidence (%) SIR
Skin cancers
Represent 24%-54% of all cancers, average 37%
   Overall (non-melanoma)       0.9-11.6 2.1-70, average 24
   Squamous cell cancer       0.6-15.3 Not reported
   Basal cell cancer       0.6-10.6 Not reported
   KS     0.2-1.4 128-144
   Melanoma     0.2-3.9 4.4
Post-transplant lymphoproliferative disorders
Represent 4%-57% of all cancers, average 25%
   Overall     0.5-2.9 3.9-21, average 12
   Hodgkin’s lymphoma 0.001-0.4 8.2-8.9
   Non-Hodgkin's lymphoma     0.8-3.7   3.5-37.3
Solid organ cancers
Represent 24%-75% of all cancers, average 48%
   Overall     1.4-7.5 1.4-3.1, average 2.3
   Lip             1.8   14-24.8
   Oropharyngeal     1.7-1.9   7-10
   Lung     0.6-2.4 1.4-2.0
   Stomach     0.2-0.7 0.5-3.7
   Colorectal     0.5-1.1 1.4-4.9
   Breast (in females)     0.2-0.6  0.6-1.61
   Cervix (in females)     0.7-1.4 1.3-5.7
   Prostate (in males)     0.2-1.8  0.6-1.61
1The SIR was not found to be significantly higher for transplant recipients compared with the 
reference population. Of note, studies often reported either incidence rate or SIR, but rarely both 
values. SIR: Standardized incidence ratio; KS: Kaposi’s sarcoma.
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the degree of immunosuppression that represents 
the main risk rather than the choice of agent[62,77,78]. 
However, there is mounting evidence that mTOR inhi-
bitors have protective effect against NMSC due to 
their aforementioned anti-proliferative properties[72,77], 
especially in renal transplant recipients. In a randomized 
trial, converting renal transplant recipients with NMSC 
from CNI to sirolimus based immunosuppression was 
associated with a reduced risk of subsequent NMSC 
(relative risk 0.56, 95%CI: 0.32-0.98) and longer 
recurrence free interval (15 mo vs 7 mo, P = 0.02)[79]. 
However, similar evidence in LT recipients is currently 
lacking.
Kaposi’s sarcoma is related to human herpes virus-8 
(HHV-8) and occurs only in immunocompromised indi-
viduals. The incidence of KS after LT reflects the pre-
valence of HHV-8 (also known as Kaposi’s sarcoma-
associated herpes virus), with high rates reported in the 
Mediterranean region[80,81]. Not surprisingly the highest 
rates and SIR (commonly > 100) for KS post LT are 
reported in Italian transplant series[11,17,47].
Post-transplant lymphoproliferative disorders
The term PTLD encompasses a broad spectrum of 
lymphoproliferative disorders observed in the immuno-
compromised solid organ transplant recipients. It is 
the second most common malignancy in LT recipients, 
and is notable in its wide age distribution, extending to 
the very young[14]. The rate of PTLD is lower in the liver 
compared to other solid organ recipients[82], likely due 
to lower immunosuppression levels needed to prevent 
liver allograft rejection, and possibly a smaller number 
of donor lymphocytes in the graft[83]. The other factor 
driving PTLD risk is EBV infection, with associated PTLD 
generally occurring earlier, in the first 12 to 18 mo, after 
LT and involving younger patients[82,84]. Infection with 
EBV and immunosuppression appear to play crucial 
roles in the pathogenesis of PTLD. EBV mismatch 
between donor and recipient of LT increases the risk 
of PTLD by 70 fold[85,86]. Primary infection with EBV 
after LT also increases the risk significantly[87]. Primary 
EBV or latent (of virus within B cells) infection can 
stimulate B cell proliferation and transformation[88]. EBV 
associated PTLD occurs three times more frequently in 
pediatric patients[87,89]. This is likely a reflection of the 
EBV negative status of pediatric recipient, whereas EBV 
infects 90% of the adults worldwide[90].
Another important phenotype of PTLD develops 
later post LT in the absence of EBV infection involves 
older recipients and carries a worse prognosis[82]. The 
pathogenesis of EBV negative PTLD is uncertain[91], 
but some risk factors were described in a study of 480 
adult LT recipient PTLD in France, where 16 developed 
PTLD[92]. These were age above 50, LT for hepatitis C 
virus (HCV) or alcoholic cirrhosis, and the use of anti-
lymphocyte antibodies such as muromonab, the latter 
reported by others[82,87]. The use of anti-thymocyte 
globulins in LT for HCV cirrhosis augmented PTLD risk 
in another study (27% for HCV vs 6.4% for non-HCV 
cases, P = 0.08)[93]. When compared to lymphomas in 
the immunocompetent population, PTLD are more likely 
to exhibit extra-nodal involvement, high-grade and poor 
outcomes[94]. Factors which confer a poor prognosis 
with PTLD are; high grade or stage at diagnosis[43], 
T cell disease[95], central nervous system and bone 
marrow involvement[96,97], poor performance status[98], 
higher number of extra-nodal sites[98], and EBV negative 
disease[43,85,99].
Solid organ cancers
Like PTLD, this category of de novo malignancy carries 
significant risk of mortality post LT, but is a term loosely 
used to group a wide range of tumor types and organ 
involved. Some characteristics of risk are evident in 
relation to subgroups of solid organ cancers, including 
aerodigestive, gastrointestinal, genitourinary and gyneco-
logic systems.
Aerodigestive cancers
Aerodigestive cancers are associated with smoking 
and alcohol use, and arise from the tissues of the 
aerodigestive tract, which include the respiratory tract 
and the upper part of the digestive tract (including the 
lips, mouth, tongue, nose, throat, vocal cords, and part 
of the esophagus and windpipe). These are largely 
reported as head and neck cancers and lung cancer post 
LT.
A meta-analysis of studies examining head and neck 
cancer after LT found an overall SIR of 3.8 (95%CI: 
2.7-4.9)[100]. They develop at mean post LT intervals 
that range from 34 to 61 mo[3-5,92,101]. Liver transplant 
recipients with a history of tobacco use and ALD are at 
high risk for developing head and neck cancers[7,12,102], 
and in some studies only developed in patients with a 
history of ALD[6,103]. 
In a large study encompassing all solid organ trans-
plants in the United States, the SIR for lung cancer 
after LT was found to be 1.95 (95%CI: 1.74-2.19)[14]. 
Lung cancer develops at mean post LT intervals ranging 
from 42 to 50 mo[3,5,28,61,101]. The main risk factors for 
lung cancer, similar to the general population, in LT 
recipients was smoking[2,7,12,54]. Those transplanted for 
ALD also had increased risk of lung cancer compared 
to those transplanted for other causes (4.3% vs 0.7%, 
P < 0.001), though tobacco use which prevalent in this 
population may confound these observations[7,12,54]. Post 
LT lung cancer is commonly diagnosed in advanced 
stages[3,5,54], suggesting the need for diligent surveillance 
programs in the high risk population (smokers and 
those transplanted for ALD). It remains unclear how 
long tobacco and alcohol related cancer risk persist 
following cessation. 
Gastrointestinal cancers
The most common gastrointestinal cancer seen in solid 
organ transplant recipients is colon cancer[14]. The SIR 
for colon cancer in LT recipients ranges from 1.4 to as 
high 27.3 in subsets of high risk patients with PSC[16,17,45]. 
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Patients receiving LT for PSC are at particularly high 
risk for colon cancer, due to the association with 
IBD[12,45,104-106]. In the study by Watt et al[12] PSC alone (HR 
= 1.9, P = 0.12) was not a risk factor for gastrointestinal 
malignancy, whereas patients with PSC, IBD and intact 
colons had a significant cancer risk (HR = 3.51, 95%CI: 
1.48-8.36, P = 0.005). Colon cancer was more common 
in LT recipients with ulcerative colitis (SIR = 27.3 vs 
3.5), than those without it, particularly in patients older 
than 40 (SIR = 4.8 vs 1 in younger patients)[45]. Longer 
duration of IBD and more extensive colonic involvement 
increase the risk for colorectal cancer in LT recipients 
with PSC[104-106]. Colorectal cancer develops at a younger 
age in LT recipients compared with the general popu-
lation, and has a worse prognosis[107,108]. A relatively 
high incidence of colon and stomach cancer have been 
reported in a South Korean study[67], with otherwise 
relatively low (2.2%-2.3%) de novo malignancy inci-
dence rates reported in East Asian studies[67,69].
Genitourinary and gynecologic cancers
Registry studies indicate an increased SIR of some 
(cervical, vulvar, bladder and kidney) but not all geni-
tourinary or gender-specific (breast, prostate, uterine, 
ovarian) cancers following solid organ transplant[10,14-17,45], 
In the largest of these, there was a slightly lower SIR for 
breast and prostate cancer in transplant recipients[14]. 
Cervical cancer risk was significantly elevated in one 
series (SIR = 30.7)[17], and other human papilloma virus 
related cancers (vulvar, vaginal, anal, penile) all appear 
to have higher SIR (range 2.4-7.6) relative to the gene-
ral population[14]. Bladder cancer risk is increased in a 
number of studies, with a range of SIR value from 1.5 to 
2.4[14-16], and were noted to develop late (10 years) post 
LT in one cohort[47]. 
SURVIVAL AFTER DE NOVO NON-SKIN 
CANCERS
In a comparison of patients from a solid organ trans-
plant cancer registry with a general population from the 
Surveillance, Epidemiology, and End Results database,
transplant patients were more likely to be diagnosed 
with American Joint Commission on Cancer stage > 
2 cancers, and worse cancer-specific survival[109]. The 
relative risk of cancer-related mortality compared to the 
general population was 2.9 (95%CI: 1.59-5.11)[7]. In a 
large single center study de novo malignancy, excluding 
NMSC, was a leading category of mortality risk (14.2%), 
along with infections (15%), disease recurrence (13%) 
and cardiovascular (9%) complications[2]. Patient survival 
rates at 1.3 and 5 years after diagnosis of de novo 
malignancy were 55%, 36%, and 27% compared with 
100%, 100% and 67% for patients with only NMSC, P 
= 0.001, respectively[2]. Similarly, de novo malignancy 
excluding NMSC was associated with an increased risk 
of mortality [HR = 4.9 (95%CI: 1.67-14.2), P = 0.003] 
in another large series[40], and probability of death after 
diagnosis was 40% at 1 year, and 55% at 5 years, 
respectively[12].
There is considerable variability in reported survival 
after PTLD, with median survival as low as 2 mo (95%CI: 
0.3-3.5 mo) in one study[36], likely as a result of hete-
rogeneity in risk characteristics of PTLD[95]. Longer 
median survival intervals (27 mo to 35 mo) are noted in 
other LT series[12,14], with reported 1 and 5 year survival 
rates of 56% and 46%, respectively[82]. Pediatric LT 
recipients with PTLD appear to have better outcomes, 
with median survival of 8.2 years and reported 10 years 
survival rates of 59%[85,96], and no reported mortality in 
some series[94]. Advanced stage, Burkitt or Burkitt-like 
PTLD, and c-myc translocations indicated poor prognosis 
and short survival in pediatric PTLD[96]. 
The reported site-specific cancer survival rates for 
the aforementioned solid organ cancer categories are: 
Oropharyngeal cancer 1 and 5 year survival of 43% 
to 78% and 56% respectively, lung cancer 1 and 5 
year survival of 41% to 43% and 16% respectively, 
gastrointestinal cancers 1 and 5 year survival of 67% to 
80% and 52% respectively, and genitourinary cancers 
1 and 5 year survival of 79%-100% and 71% respec-
tively[3,12]. 
SURVEILLANCE 
The increased risk and mortality associated with de 
novo malignancies underlines the need for surveillance 
strategies to detect tumors at earlier stages, allow more 
effective treatments, and improve survival. However, 
there are no standardized surveillance protocols for LT 
recipients at present. Routine follow up visits alone were 
only capable of detecting 12% of the non-skin cancers 
in one series, and annual visits resulted in identifying 
half of all malignancies in another[8,9]. Poor compliance 
with surveillance protocols was also cited as a limitation 
in a study where active surveillance identified only 3 
of 28 non-skin cancers[7]. These data further highlight 
the need for regimented surveillance strategies in this 
regard. 
In a compelling study, the incidence and outcome of 
de novo malignancy were compared before and after 
institution of an intensified surveillance protocol which 
included: Annual chest and abdominal computerized 
tomography (CT), urological, gynecological (pap smear 
and mammography) and dermatological examination, 
and colonoscopies every 5 years[18]. With a historical 
surveillance program consisting of annual chest radio-
graphs and abdominal ultrasounds serving as the 
reference comparator, the detection rate for de novo mali-
gnancies increased from 4.9% to 13% with intensified 
surveillance (P = 0.001), fewer tumors were diagnosed 
at stage Ⅲ or Ⅳ (46% vs 75%), and median survival 
following a diagnosis of non-skin cancer increased from 
1.2 to 3.3 years (P = 0.001)[18]. 
At another center, a similarly multifaceted survei-
llance protocol that included: (1) urinalysis, chest radio-
graphs and abdominal ultrasounds performed every 
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6 mo in the first year post LT and annually thereafter; 
(2) mammography every two years; (3) colonoscopy 
every 7-10 years if no adenomas were detected; 
and (4) in patients with smoking history, an annual 
otolaryngological evaluation and low dose CT of the 
chest after 2006[110]. Patients that were diagnosed with 
de novo malignancy through active surveillance had 
better survival (all were alive after 25 mo of follow up) 
compared with patients diagnosed with symptomatic 
disease or incidentally (median survival of 13.5 mo) (P 
= 0.002)[110]. The use of annual low dose chest CT in LT 
recipients with more than 10 pack years of cumulative 
smoking history led to a diagnosis of early stage lung 
cancer in 12% of patients[111].
Additionally, special populations amongst LT recipient 
and the specialized surveillance strategies that are or 
may be warranted for them include those with: (1) 
underlying PSC and IBD, or IBD alone of more than 8-10 
years duration with annual surveillance colonoscopy; (2) 
a history of human papilloma virus infection with annual 
pap smear in females, and annual genital and anal 
pap/scraping in both genders; and (3) patients from the 
Mediterranean region with testing of HHV-8 titers due to 
increased prevalence and association with risk of KS[112].
PREVENTATIVE MEASURES
Smoking is a major risk factor for cancer, especially 
nasopharyngeal cancers and lung cancer, as well car-
diovascular disease related mortality[56], and smoking 
cessation should be counseled as early as possible. 
Regular application of broad spectrum sunscreen (SPF 
> 50, with high-UVA absorption) over sun-exposed 
areas in solid organ transplant recipients, in conjunction 
with counseling of excessive sun exposure avoidance, 
reduced the risk of actinic keratosis, invasive SCC and 
BCC from developing in a prospective case control 
study in solid organ transplant recipients[113]. Protective 
clothing has also been shown to protect against UV 
radiation[114]. The minimization of immunosuppression 
without risking graft rejection is limited by the lack of 
accurate markers of over or under immunosuppression, 
but would likely to attenuate the risk of de novo mali-
gnancy in LT recipient. There is also insufficient evidence 
to guide the routine use of mTOR inhibitors in at risk 
patients, but those studies are ongoing[115-120].
CONCLUSION 
Liver transplant recipients are at increased risk of cancer 
when compared to the general population, and the most 
commonly encountered cancers are NMSC, PTLD, and 
aerodigestive. They are due mainly due to the effects 
of immunosuppression and latent oncogenic viruses 
prevalent in the population. Important risk factors for 
development of de novo malignancy include age, degree 
of immunosuppression, history of smoking and alcohol 
abuse and transplantation for PSC and ALD. De novo 
malignancies, excluding NMSC, represent a major risk 
category for post LT mortality. There are no standardized 
surveillance protocols for de novo malignancy post 
LT, but available evidence supports adoption of some 
consistent surveillance strategies. Minimization of im-
munosuppression and attention and counseling related 
to other risk factors in LT recipients may reduce an 
individual’s risk of developing cancers post LT, but more 
evidence is needed to optimize care. 
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